SteelPeak Wealth LLC Raises Position in Merck & Co., Inc. $MRK

SteelPeak Wealth LLC lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 29.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 190,521 shares of the company’s stock after purchasing an additional 43,834 shares during the quarter. SteelPeak Wealth LLC’s holdings in Merck & Co., Inc. were worth $20,213,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Darwin Wealth Management LLC increased its stake in shares of Merck & Co., Inc. by 237.4% during the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after acquiring an additional 216 shares during the last quarter. Kilter Group LLC purchased a new position in shares of Merck & Co., Inc. during the 2nd quarter worth about $27,000. Barnes Dennig Private Wealth Management LLC boosted its position in shares of Merck & Co., Inc. by 302.3% in the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after acquiring an additional 266 shares during the last quarter. Evolution Wealth Management Inc. purchased a new stake in Merck & Co., Inc. in the second quarter valued at approximately $31,000. Finally, United Financial Planning Group LLC purchased a new stake in Merck & Co., Inc. in the third quarter valued at approximately $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $120.62 on Friday. The business’s 50-day simple moving average is $117.72 and its 200 day simple moving average is $103.08. The company has a market cap of $298.21 billion, a P/E ratio of 16.57, a PEG ratio of 2.44 and a beta of 0.26. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. During the same quarter in the prior year, the business earned $1.72 EPS. Merck & Co., Inc.’s quarterly revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, sell-side analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be paid a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio is 46.70%.

Insiders Place Their Bets

In other Merck & Co., Inc. news, CEO Robert M. Davis sold 47,434 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $118.04, for a total value of $5,599,109.36. Following the transaction, the chief executive officer owned 443,602 shares in the company, valued at $52,362,780.08. The trade was a 9.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Caroline Litchfield sold 41,997 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total transaction of $5,023,261.17. Following the completion of the transaction, the chief financial officer directly owned 90,192 shares of the company’s stock, valued at approximately $10,787,865.12. The trade was a 31.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 320,176 shares of company stock valued at $38,281,735. Corporate insiders own 0.13% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: EU approval expands KEYTRUDA use to PD‑L1 positive, platinum‑resistant ovarian cancer — opens a new commercial indication in Europe for an established franchise, which can drive incremental revenue and utilization in a high‑unmet‑need setting. Merck Broadens Cancer And Eye Disease Pipeline As Investors Weigh Future Growth
• Positive Sentiment: Merck initiated a pivotal Phase 2b/3 trial of MK‑8748 (Tiespectus) for wet AMD — a promising ophthalmology program that, if successful, adds a non‑oncology growth vector and diversifies long‑term revenue streams. Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus)
• Positive Sentiment: Positive Phase 3 CORALreef results for oral PCSK9 inhibitor (enlicitide decanoate) — if approved, an oral PCSK9 could be a major commercial opportunity in cardiovascular prevention and complement existing lipid therapies. Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Detailed Phase 2 CADENCE data for WINREVAIR released — adds evidence to a respiratory program that management can highlight to investors as part of a broader R&D pipeline story. Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck KGaA acquisition of JSR chromatography business noted in the press — this concerns Merck KGaA (a different company) and is unlikely to meaningfully affect Merck & Co.’s (MRK) near‑term fundamentals. Merck KGaA acquires JSR chromatography
• Negative Sentiment: New proposal from former President Trump to impose up to 100% tariffs on imported medicines (with carve‑outs) increases regulatory and pricing uncertainty for the sector; even with exemptions, the proposal raises near‑term headline risk and could pressure sentiment toward large pharma names like MRK until policy clarity emerges. Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions
• Negative Sentiment: Sector policy debate over drug‑pricing deals continues (Lilly warns against locking pricing deals into law) — ongoing political scrutiny increases the chance of policy actions that could cap pricing or change reimbursement, a headwind for long‑term margin visibility. Lilly Pushes Back on Making Drug Price Deals Permanent

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on MRK shares. TD Cowen increased their price target on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a research note on Tuesday, January 20th. Royal Bank Of Canada reissued an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Cantor Fitzgerald upped their price objective on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. BMO Capital Markets raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $82.00 to $130.00 in a research report on Thursday, December 18th. Finally, Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $127.13.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.